Quarterly report · Q3
8129.TEDINET S100SULP
Period2023-04-01 → 2023-12-31
Filed2024-02-14
StandardJapan GAAP
ConsolidatedYes
Data checks12 of 12 passed
Key figures · 36
| Metric | Value | Period | Scope | Source row |
|---|---|---|---|---|
| Revenue | ¥1.12T | 2023-04-01 → 2023-12-31 | Cons. | Net sales |
| Revenue | ¥1.39T | 2022-04-01 → 2023-03-31 | Cons. | Net sales (5-year summary) |
| Revenue | ¥1.06T | 2022-04-01 → 2022-12-31 | Cons. | Net sales |
| Operating income | ¥11.6bn | 2023-04-01 → 2023-12-31 | Cons. | Operating income |
| Operating income | ¥11.2bn | 2022-04-01 → 2022-12-31 | Cons. | Operating income |
| Ordinary income | ¥13.6bn | 2023-04-01 → 2023-12-31 | Cons. | Ordinary income |
| Ordinary income | ¥19.2bn | 2022-04-01 → 2023-03-31 | Cons. | Ordinary income loss (5-year summary) |
| Ordinary income | ¥13.4bn | 2022-04-01 → 2022-12-31 | Cons. | Ordinary income |
| Profit before tax | ¥20.3bn | 2023-04-01 → 2023-12-31 | Cons. | Income before income taxes |
| Profit before tax | ¥14.4bn | 2022-04-01 → 2022-12-31 | Cons. | Income before income taxes |
| Net income (owners) | ¥13.5bn | 2023-04-01 → 2023-12-31 | Cons. | Profit loss attributable to owners of parent |
| Net income (owners) | ¥13.6bn | 2022-04-01 → 2023-03-31 | Cons. | Profit loss attributable to owners of parent (5-year summary) |
| Net income (owners) | ¥9.5bn | 2022-04-01 → 2022-12-31 | Cons. | Profit loss attributable to owners of parent |
| Net income | ¥13.5bn | 2023-04-01 → 2023-12-31 | Cons. | Profit loss |
| Net income | ¥9.6bn | 2022-04-01 → 2022-12-31 | Cons. | Profit loss |
| Total assets | ¥804.9bn | at 2023-12-31 | Cons. | Assets |
| Total assets | ¥715.3bn | at 2023-03-31 | Cons. | Assets |
| Total assets | ¥794.4bn | at 2022-12-31 | Cons. | Total assets (5-year summary) |
| Total liabilities | ¥561.2bn | at 2023-12-31 | Cons. | Liabilities |
| Total liabilities | ¥472.4bn | at 2023-03-31 | Cons. | Liabilities |
| Net assets / equity | ¥243.7bn | at 2023-12-31 | Cons. | Net assets |
| Net assets / equity | ¥242.9bn | at 2023-03-31 | Cons. | Net assets |
| Net assets / equity | ¥240.4bn | at 2022-12-31 | Cons. | Net assets (5-year summary) |
| Cash and deposits | ¥128.9bn | at 2023-12-31 | Cons. | Cash and deposits |
| Cash and deposits | ¥86.2bn | at 2023-03-31 | Cons. | Cash and deposits |
| EPS (basic) | ¥207.25 | 2023-04-01 → 2023-12-31 | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥73.14 | 2023-10-01 → 2023-12-31d | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥196.7 | 2022-04-01 → 2023-03-31 | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥136.09 | 2022-04-01 → 2022-12-31 | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥85.9 | 2022-10-01 → 2022-12-31d | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (diluted) | ¥186.2 | 2023-04-01 → 2023-12-31 | Cons. | Diluted earnings per share (5-year summary) |
| EPS (diluted) | ¥180.67 | 2022-04-01 → 2023-03-31 | Cons. | Diluted earnings per share (5-year summary) |
| EPS (diluted) | ¥125.1 | 2022-04-01 → 2022-12-31 | Cons. | Diluted earnings per share (5-year summary) |
| Equity ratio | 30.3% | at 2023-12-31 | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 33.9% | at 2023-03-31 | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 30.2% | at 2022-12-31 | Cons. | Equity to asset ratio (5-year summary) |
Periods use the dates stated in the filing. d = earlier-year period dated by calendar; v = that date confirmed by the company's own earlier filing.
Segments · 46
| Segment | Item | Period | Value |
|---|---|---|---|
| Reconciling Itemsreconciling | revenue | 2023-04-01 → 2023-12-31 | −¥44.5bn |
| Reconciling Itemsreconciling | revenue intersegment | 2023-04-01 → 2023-12-31 | −¥44.5bn |
| Reconciling Itemsreconciling | segment profit | 2023-04-01 → 2023-12-31 | −¥2.6bn |
| jpcrp040300-q3r_E02608-000Dispensing Pharmacyreportable segment | revenue | 2023-04-01 → 2023-12-31 | ¥70.4bn |
| jpcrp040300-q3r_E02608-000Dispensing Pharmacyreportable segment | revenue external | 2023-04-01 → 2023-12-31 | ¥70.4bn |
| jpcrp040300-q3r_E02608-000Dispensing Pharmacyreportable segment | revenue intersegment | 2023-04-01 → 2023-12-31 | ¥9m |
| jpcrp040300-q3r_E02608-000Dispensing Pharmacyreportable segment | segment profit | 2023-04-01 → 2023-12-31 | ¥1.4bn |
| jpcrp040300-q3r_E02608-000Medical Products Manufacturing And Salesreportable segment | revenue | 2023-04-01 → 2023-12-31 | ¥8.0bn |
| jpcrp040300-q3r_E02608-000Medical Products Manufacturing And Salesreportable segment | revenue external | 2023-04-01 → 2023-12-31 | ¥1.8bn |
| jpcrp040300-q3r_E02608-000Medical Products Manufacturing And Salesreportable segment | revenue intersegment | 2023-04-01 → 2023-12-31 | ¥6.2bn |
| jpcrp040300-q3r_E02608-000Medical Products Manufacturing And Salesreportable segment | segment profit | 2023-04-01 → 2023-12-31 | ¥686m |
| jpcrp040300-q3r_E02608-000Medical Products Retailreportable segment | revenue | 2023-04-01 → 2023-12-31 | ¥1.08T |
| jpcrp040300-q3r_E02608-000Medical Products Retailreportable segment | revenue external | 2023-04-01 → 2023-12-31 | ¥1.04T |
| jpcrp040300-q3r_E02608-000Medical Products Retailreportable segment | revenue intersegment | 2023-04-01 → 2023-12-31 | ¥37.3bn |
| jpcrp040300-q3r_E02608-000Medical Products Retailreportable segment | segment profit | 2023-04-01 → 2023-12-31 | ¥11.8bn |
| jpcrp040300-q3r_E02608-000Other Related Businessreportable segment | revenue | 2023-04-01 → 2023-12-31 | ¥4.4bn |
| jpcrp040300-q3r_E02608-000Other Related Businessreportable segment | revenue external | 2023-04-01 → 2023-12-31 | ¥3.4bn |
| jpcrp040300-q3r_E02608-000Other Related Businessreportable segment | revenue intersegment | 2023-04-01 → 2023-12-31 | ¥1.0bn |
| jpcrp040300-q3r_E02608-000Other Related Businessreportable segment | segment profit | 2023-04-01 → 2023-12-31 | ¥258m |
| Total Of Reportable Segments And Otherssegment total | revenue | 2023-04-01 → 2023-12-31 | ¥1.16T |
| Total Of Reportable Segments And Otherssegment total | revenue external | 2023-04-01 → 2023-12-31 | ¥1.12T |
| Total Of Reportable Segments And Otherssegment total | revenue intersegment | 2023-04-01 → 2023-12-31 | ¥44.5bn |
| Total Of Reportable Segments And Otherssegment total | segment profit | 2023-04-01 → 2023-12-31 | ¥14.2bn |
| Reconciling Itemsreconciling | revenue | 2022-04-01 → 2022-12-31 | −¥43.4bn |
| Reconciling Itemsreconciling | revenue intersegment | 2022-04-01 → 2022-12-31 | −¥43.4bn |
| Reconciling Itemsreconciling | segment profit | 2022-04-01 → 2022-12-31 | −¥1.1bn |
| jpcrp040300-q3r_E02608-000Dispensing Pharmacyreportable segment | revenue | 2022-04-01 → 2022-12-31 | ¥68.8bn |
| jpcrp040300-q3r_E02608-000Dispensing Pharmacyreportable segment | revenue external | 2022-04-01 → 2022-12-31 | ¥68.8bn |
| jpcrp040300-q3r_E02608-000Dispensing Pharmacyreportable segment | revenue intersegment | 2022-04-01 → 2022-12-31 | ¥4m |
| jpcrp040300-q3r_E02608-000Dispensing Pharmacyreportable segment | segment profit | 2022-04-01 → 2022-12-31 | ¥1.7bn |
| jpcrp040300-q3r_E02608-000Medical Products Manufacturing And Salesreportable segment | revenue | 2022-04-01 → 2022-12-31 | ¥7.4bn |
| jpcrp040300-q3r_E02608-000Medical Products Manufacturing And Salesreportable segment | revenue external | 2022-04-01 → 2022-12-31 | ¥1.6bn |
| jpcrp040300-q3r_E02608-000Medical Products Manufacturing And Salesreportable segment | revenue intersegment | 2022-04-01 → 2022-12-31 | ¥5.8bn |
| jpcrp040300-q3r_E02608-000Medical Products Manufacturing And Salesreportable segment | segment profit | 2022-04-01 → 2022-12-31 | ¥715m |
| jpcrp040300-q3r_E02608-000Medical Products Retailreportable segment | revenue | 2022-04-01 → 2022-12-31 | ¥1.02T |
| jpcrp040300-q3r_E02608-000Medical Products Retailreportable segment | revenue external | 2022-04-01 → 2022-12-31 | ¥986.2bn |
| jpcrp040300-q3r_E02608-000Medical Products Retailreportable segment | revenue intersegment | 2022-04-01 → 2022-12-31 | ¥36.4bn |
| jpcrp040300-q3r_E02608-000Medical Products Retailreportable segment | segment profit | 2022-04-01 → 2022-12-31 | ¥9.4bn |
| jpcrp040300-q3r_E02608-000Other Related Businessreportable segment | revenue | 2022-04-01 → 2022-12-31 | ¥4.9bn |
| jpcrp040300-q3r_E02608-000Other Related Businessreportable segment | revenue external | 2022-04-01 → 2022-12-31 | ¥3.8bn |
| jpcrp040300-q3r_E02608-000Other Related Businessreportable segment | revenue intersegment | 2022-04-01 → 2022-12-31 | ¥1.2bn |
| jpcrp040300-q3r_E02608-000Other Related Businessreportable segment | segment profit | 2022-04-01 → 2022-12-31 | ¥449m |
| Total Of Reportable Segments And Otherssegment total | revenue | 2022-04-01 → 2022-12-31 | ¥1.10T |
| Total Of Reportable Segments And Otherssegment total | revenue external | 2022-04-01 → 2022-12-31 | ¥1.06T |
| Total Of Reportable Segments And Otherssegment total | revenue intersegment | 2022-04-01 → 2022-12-31 | ¥43.4bn |
| Total Of Reportable Segments And Otherssegment total | segment profit | 2022-04-01 → 2022-12-31 | ¥12.3bn |
Segment names come from EDINET member IDs; not yet mapped to a common taxonomy.
All source rows · 419
| Item | Context | Value | Unit |
|---|---|---|---|
| Transactions with other segments | CurrentYTDDuration_jpcrp040300-q3r_E02608-000OtherRelatedBusinessReportableSegmentMember | 1035000000 | JPY |
| Transactions with other segments | CurrentYTDDuration_TotalOfReportableSegmentsAndOthersMember | 44498000000 | JPY |
| Transactions with other segments | CurrentYTDDuration_ReconcilingItemsMember | -44498000000 | JPY |
| Transactions with other segments | CurrentYTDDuration | － | JPY |
| Net sales | CurrentYTDDuration_jpcrp040300-q3r_E02608-000MedicalProductsRetailReportableSegmentsMember | 1081258000000 | JPY |
| Net sales | CurrentYTDDuration_jpcrp040300-q3r_E02608-000DispensingPharmacyReportableSegmentsMember | 70364000000 | JPY |
| Net sales | CurrentYTDDuration_jpcrp040300-q3r_E02608-000MedicalProductsManufacturingAndSalesReportableSegmentMember | 7984000000 | JPY |
| Net sales | CurrentYTDDuration_jpcrp040300-q3r_E02608-000OtherRelatedBusinessReportableSegmentMember | 4440000000 | JPY |
| Net sales | CurrentYTDDuration_TotalOfReportableSegmentsAndOthersMember | 1164048000000 | JPY |
| Net sales | CurrentYTDDuration_ReconcilingItemsMember | -44498000000 | JPY |
| Net sales | CurrentYTDDuration | 1119549000000 | JPY |
| Operating income | CurrentYTDDuration_jpcrp040300-q3r_E02608-000MedicalProductsRetailReportableSegmentsMember | 11758000000 | JPY |
| Operating income | CurrentYTDDuration_jpcrp040300-q3r_E02608-000DispensingPharmacyReportableSegmentsMember | 1446000000 | JPY |
| Operating income | CurrentYTDDuration_jpcrp040300-q3r_E02608-000MedicalProductsManufacturingAndSalesReportableSegmentMember | 686000000 | JPY |
| Operating income | CurrentYTDDuration_jpcrp040300-q3r_E02608-000OtherRelatedBusinessReportableSegmentMember | 258000000 | JPY |
| Operating income | CurrentYTDDuration_TotalOfReportableSegmentsAndOthersMember | 14150000000 | JPY |
| Operating income | CurrentYTDDuration_ReconcilingItemsMember | -2568000000 | JPY |
| Operating income | CurrentYTDDuration | 11581000000 | JPY |
| Document title cover page | FilingDateInstant | Original text (Japanese)四半期報告書 | |
| Clause of stipulation cover page | FilingDateInstant | Original text (Japanese)金融商品取引法第24条の４の７第１項 | |
| Place of filing cover page | FilingDateInstant | Original text (Japanese)関東財務局長 | |
| Filing date cover page | FilingDateInstant | 2024-02-14 | |
| Quarterly accounting period cover page | FilingDateInstant | Original text (Japanese)第76期第３四半期(自 2023年10月１日 至 2023年12月31日) | |
| Company name cover page | FilingDateInstant | Original text (Japanese)東邦ホールディングス株式会社 | |
| Company name in english cover page | FilingDateInstant | TOHO HOLDINGS CO.,LTD. | |
| Title and name of representative cover page | FilingDateInstant | Original text (Japanese)代表取締役ＣＥＯ 有働 敦 | |
| Address of registered headquarter cover page | FilingDateInstant | Original text (Japanese)東京都世田谷区代沢五丁目２番１号 | |
| Telephone number address of registered headquarter cover page | FilingDateInstant | ０３（６７００）８７４５ | |
| Name of contact person address of registered headquarter cover page | FilingDateInstant | Original text (Japanese)管理本部長 兼 財務部長 水澤 義昭 | |
| Nearest place of contact cover page | FilingDateInstant | Original text (Japanese)東京都中央区八重洲二丁目２番１号東京ミッドタウン八重洲八重洲セントラルタワー９階 | |
| Telephone number nearest place of contact cover page | FilingDateInstant | ０３（６７００）８７４５ | |
| Name of contact person nearest place of contact cover page | FilingDateInstant | Original text (Japanese)管理本部長 兼 財務部長 水澤 義昭 | |
| Place for public inspection cover page (text) | FilingDateInstant | Text · Plus | |
| Edinet code | FilingDateInstant | E02608 | |
| Fund code | FilingDateInstant | － | |
| Security code | FilingDateInstant | 81290 | |
| Filer name in japanese | FilingDateInstant | Original text (Japanese)東邦ホールディングス株式会社 | |
| Filer name in english | FilingDateInstant | TOHO HOLDINGS CO.,LTD. | |
| Fund name in japanese | FilingDateInstant | － | |
| Fund name in english | FilingDateInstant | － | |
| Cabinet office ordinance | FilingDateInstant | Original text (Japanese)企業内容等の開示に関する内閣府令 | |
| Document type | FilingDateInstant | Original text (Japanese)第四号の三様式 | |
| Accounting standards | FilingDateInstant | Japan GAAP | |
| Whether consolidated financial statements are prepared | FilingDateInstant | true | |
| Industry code when consolidated financial statements are prepared in accordance with industry specific regulations | FilingDateInstant | cte | |
| Industry code when financial statements are prepared in accordance with industry specific regulations | FilingDateInstant | － | |
| Current fiscal year start date | FilingDateInstant | 2023-04-01 | |
| Current period end date | FilingDateInstant | 2023-12-31 | |
| Type of current period | FilingDateInstant | Q3 | |
| Current fiscal year end date | FilingDateInstant | 2024-03-31 |
Every row of the EDINET CSV. Item names are the XBRL element names; filed text is kept in its original Japanese. Filed text is available on Plus and Pro.
Data checks · 12 of 12 passed
| balance sheet identity | pass |
| balance sheet identity | pass rounding |
| dei present | pass |
| period resolution | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · revenue | pass |
| statement vs summary · revenue | pass |
| statement vs summary · total assets | pass |
| statement vs summary · total assets | pass |